Company / Current Liabilities
Lineage Cell Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$11.4M
FY2025
5-year range
$11.4M / $47.1M
FY2021-FY2025
Trend
-18.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has declined for 4 consecutive years, from $47M in FY2021 to $11M in FY2025.
Based on SEC 10-K filings.
$11M in FY2025 with a 5-year CAGR of +7.9%.
Improved from $18M to $11M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -15.7%
- 5-Year CAGR
- +7.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- Lineage Cell Therapeutics, Inc.'s current liabilities has declined for 4 consecutive years.
- 5-year CAGR of +7.9%, indicating consistent growth.
- In FY2025, current liabilities decreased 18.7% year-over-year.
- Peak current liabilities was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.4M | -18.7% |
| FY2024 | $14.0M | -22.2% |
| FY2023 | $18.0M | -5.4% |
| FY2022 | $19.0M | -59.7% |
| FY2021 | $47.1M | +506.5% |
| FY2020 | $7.8M | +19.6% |
| FY2019 | $6.5M | -4.7% |
| FY2018 | $6.8M | -1.0% |
| FY2017 | $6.9M | -22.3% |
| FY2016 | $8.8M | -29.0% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026